BRD9 and diabetes mellitus: Previous studies have shown that BRD9 inhibitors and degraders inhibit inflammatory response of macrophages by specifically blocking BRD9‐mediated induction of interferon‐stimulated gene expression.[15, 16, 17, 18] However, whether local BRD9 inhibition could attenuate the sustained inflammatory state of wounds in patients with diabetes remains to be elucidated.